Connect Biopharma Holdings (CNTB) Liabilities and Shareholders Equity (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $60.1 million the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 35.19% year-over-year to $60.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.2 million (down 15.36% YoY) and the FY2025 annual result came in at $56.1 million, down 44.64% from the prior year.
• Liabilities and Shareholders Equity rose to $60.1 million in Q1 2026 per CNTB's latest filing, from $56.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for CNTB reached as high as $238.9 million in Q2 2022 and fell as low as $56.1 million in Q4 2025.
• A 5-year average of $114.7 million and a median of $101.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity fell 16.32% — and 2025, when it sank 44.64%.
• Year by year, Liabilities and Shareholders Equity stood at $170.4 million in 2022, then retreated by 25.25% to $127.4 million in 2023, then retreated by 20.48% to $101.3 million in 2024, then plunged by 44.64% to $56.1 million in 2025, then increased by 7.12% to $60.1 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $60.1 million, $56.1 million, and $67.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.